BioPharma Clinical Trials
BioCity Biopharma's SC0062 Achieves Primary Endpoint in Phase 2 CKD Trial, Demonstrates Significant Proteinuria Reduction
BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reducti...
July 09, 2024 | News
Hinova Pharmaceuticals Secures FDA Fast Track Designation for HP518 in Treating AR+ Triple-Negative Breast Cancer
Hinova Pharmaceuticals a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food an...
July 08, 2024 | News
Calliditas Therapeutics and Viatris Initiate Phase III Trial for IgA Nephropathy in Japan
Calliditas Therapeutics AB announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in&...
July 05, 2024 | News
MEDIPAL and JCR Pharmaceuticals Announce Regulatory Review Completion for Phase I/II Trial of JR-446 in Treating Ultra-Rare Sanfilippo Syndrome Type B
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. announced the completion of the regulatory review by the Pharmaceuticals an...
July 03, 2024 | News
FDA Approves Donanemab for Early Alzheimer's: C2N Diagnostics' Biomarkers Play Crucial Role in Landmark Study
C2N Diagnostics, a leader in advanced brain health diagnostics, is closely tracking today’s decision by the U.S. Food and Drug Administration to appr...
July 03, 2024 | News
South Korea's PharmAbcine Advances Novel nAMD Treatment PMC-403 to Key Phase 1 Milestones
PharmAbcine, a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the decision to advance ...
July 02, 2024 | News
HiRO Acquires DeltaMed Solutions, Expands Across 10 Countries
Harvest Integrated Research Organization (HiRO), a full-service, boutique global CRO, is excited to announce its latest strategic move with the successful ...
July 02, 2024 | News
Alteogen Subsidiary Altos Biologics Submits MAA to EMA for ALT-L9 Aflibercept Biosimilar
Alteogen Inc. announced that its subsidiary, Altos Biologics Inc. has submitted Marketing Authorization Application (MAA) to the European Medicines Ag...
July 02, 2024 | News
Sirnaomics Completes Phase I Clinical Study of STP707 for Pancreatic Cancer with Strong Safety Profile and Promising Disease Stability
Sirnaomics , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the Group h...
July 01, 2024 | News
Harbour BioMed Resubmits BLA for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis
Harbour BioMed , a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing ...
June 27, 2024 | News
Huadong Medicine Announces Positive Phase I Clinical Trial Results for Oral GLP-1 Receptor Agonist HDM1002 in China
HUADONG MEDICINE, through its wholly-owned subsidiary Hangzhou Zhongmei HuaDong Pharmaceutical CO. LTD (Zhongmei HuaDong), has recently announced positive ...
June 27, 2024 | News
South Korea Approves Reimbursement for Antengene's XPOVIO®, Expanding Access to Relapsed/Refractory Multiple Myeloma Treatment
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...
June 27, 2024 | News
Merck Halts Phase III TrilynX Study for Xevinapant in Head and Neck Cancer Following Interim Analysis
Merck, a leading science and technology company, announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemora...
June 25, 2024 | News
FDA Approves iRegene's NouvNeu001, Marking Milestone in Parkinson's Disease Treatment
U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson's...
June 25, 2024 | News
Most Read
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
